Antoine Papiernik

I think we need to be humble in saying...

We don't know where the most efficient use of it for drug discovery, drug development.

I don't know.

And I'm speaking to pharma all day long and I don't think they know.

But they are absolutely certain that this is gonna be transformational.

If you think about the number of pharma companies who say, we're gonna be the AI driven pharma company.

I can't really tell you yet.

I don't think that the story is already written on what works and what doesn't.

I don't think so, which is why, by the way, this is a new strategy for us and it needed some dedicated people because we are hunting

is the word you'd say for strategy.

You are trying things.

I mentioned about latent labs.

I think it's fabulous, but ultimately proof will be in the pudding, right?

So if the pharma says, my God, I want to work with latent labs and generate my next 10 new drugs with latent labs, that would be awesome.

And I'm sure this, I hope it's going to happen as part of the strategy, but it's going to take a little while.

So I think anyone who tells you what works and what doesn't,

I think it's just looking at a picture, maybe.

I don't think that the film has been shot yet.

Well, look, what you described, not just, you know, what's going on at the FDA, you know, the tariffs and MFN and, you know, biosecure, and because I'm sure we'll address, you know, the question on China, all of this in a big realm of things.

And you and I have been, you know, in this business for so long, I would refer them as noise.